4.5 Review

DLX6-AS1: a putative lncRNA candidate in multiple human cancers

Journal

EXPERT REVIEWS IN MOLECULAR MEDICINE
Volume 23, Issue -, Pages -

Publisher

CAMBRIDGE UNIV PRESS
DOI: 10.1017/erm.2021.17

Keywords

Cancer biomarker; diagnosis; DLX6-AS1; long non-coding RNA; Neoplasm; treatment target

Ask authors/readers for more resources

Long non-coding RNAs (lncRNAs) play crucial roles in cancer development, with DLX6-AS1 acting as an oncogene in the development and prognosis of different cancers, affecting various signaling pathways. Different signaling pathways associated with this lncRNA may serve as biomarkers for cancer diagnosis or treatment targets.
Long non-coding RNAs (lncRNAs) have important roles in regulating the expression of genes and act as biomarkers in the initial development of different cancers. Increasing research studies have verified that dysregulation of lncRNAs occurs in various pathological processes including tumorigenesis and cancer progression. Among the different lncRNAs, DLX6-AS1 has been reported to act as an oncogene in the development and prognoses of different cancers, by affecting many different signalling pathways. This review summarises and analyses the recent research studies describing the biological functions of DLX6-AS1, its overall effect on signalling pathways and the molecular mechanisms underlying its action on the expression of genes in multiple human cancers. Our critical analysis suggests that different signalling pathways associated to this lncRNA may be used as a biomarker for diagnosis, or targets of treatment in cancers.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available